IT1237793B - Composti attivi come inibitori dell'enzima hmg-coa reduttasi - Google Patents

Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Info

Publication number
IT1237793B
IT1237793B IT02276889A IT2276889A IT1237793B IT 1237793 B IT1237793 B IT 1237793B IT 02276889 A IT02276889 A IT 02276889A IT 2276889 A IT2276889 A IT 2276889A IT 1237793 B IT1237793 B IT 1237793B
Authority
IT
Italy
Prior art keywords
hmg
inhibitors
active compounds
coa reductase
reductase enzyme
Prior art date
Application number
IT02276889A
Other languages
English (en)
Other versions
IT8922768A1 (it
IT8922768A0 (it
Inventor
Giorgio Bertolini
Cesare Casagrande
Francesco Santangelo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to IT02276889A priority Critical patent/IT1237793B/it
Publication of IT8922768A0 publication Critical patent/IT8922768A0/it
Priority to EP19900123761 priority patent/EP0433842A3/en
Priority to US07/626,762 priority patent/US5081136A/en
Priority to JP2418293A priority patent/JPH04210682A/ja
Publication of IT8922768A1 publication Critical patent/IT8922768A1/it
Application granted granted Critical
Publication of IT1237793B publication Critical patent/IT1237793B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT02276889A 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi IT1237793B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EP19900123761 EP0433842A3 (en) 1989-12-21 1990-12-11 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
US07/626,762 US5081136A (en) 1989-12-21 1990-12-13 1,2,3-triazole compounds active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
JP2418293A JPH04210682A (ja) 1989-12-21 1990-12-20 酵素ＨＭＧ−ＣｏＡレダクターゼの抑制剤として活性な化合物ならびに該化合物を含む医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Publications (3)

Publication Number Publication Date
IT8922768A0 IT8922768A0 (it) 1989-12-21
IT8922768A1 IT8922768A1 (it) 1991-06-21
IT1237793B true IT1237793B (it) 1993-06-17

Family

ID=11200250

Family Applications (1)

Application Number Title Priority Date Filing Date
IT02276889A IT1237793B (it) 1989-12-21 1989-12-21 Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Country Status (4)

Country Link
US (1) US5081136A (it)
EP (1) EP0433842A3 (it)
JP (1) JPH04210682A (it)
IT (1) IT1237793B (it)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1037616C (zh) * 1993-07-15 1998-03-04 中国科学院兰州化学物理研究所 多功能润滑油添加剂
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
IL143197A0 (en) * 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US6849257B2 (en) 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
EP1320362B1 (en) * 2000-09-20 2011-08-31 Jagotec AG Stabilised fibrate microparticles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
EP1585500B8 (en) * 2002-12-20 2017-07-26 Auritec Pharmaceuticals Coated particles for sustained-release pharmaceutical administration
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
WO2006087630A2 (en) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
AU2005332300B2 (en) 2005-05-31 2011-07-07 Mylan Laboratories, Inc. Compositions comprising nebivolol
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US20080057590A1 (en) * 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US10568860B2 (en) 2006-08-30 2020-02-25 Kowa Co., Ltd. Pharmaceutical composition containing statin-encapsulated nanoparticle
EP1921072A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
KR20100015343A (ko) * 2007-03-01 2010-02-12 컨커스 헬스 사이언스 엘엘씨 이노시톨 니아시네이트의 이성질체 및 그 용도
CA2684308A1 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2009102761A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
KR20120139723A (ko) 2010-02-01 2012-12-27 더 호스피탈 포 식 칠드런 재발협착증의 치료 및 예방을 위한 원격 허혈 처치
CA2795053A1 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
SG10201908576VA (en) 2010-04-08 2019-10-30 Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
EP2638035B1 (en) 2010-11-09 2014-12-17 F.Hoffmann-La Roche Ag Triazole derivatives as ligands for Gaba receptors
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
ES2786506T3 (es) 2012-08-01 2020-10-13 Zahra Tavakoli Composiciones congeladas fluidas que comprenden un agente terapéutico
BR112015024234B1 (pt) 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
DK3206672T3 (en) 2015-10-27 2018-06-18 Eupraxia Pharmaceuticals Inc Formulations for sustained release of local anesthetics
KR101777634B1 (ko) * 2016-01-18 2017-09-12 연성정밀화학(주) 3-((2s,5s)-4-메틸렌-5-(3-옥소프로필)테트라히드로퓨란-2-일)프로판올 유도체의 제조방법 및 이를 위한 중간체
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
EP4126858B1 (en) 2020-03-26 2026-03-18 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE62906T1 (de) * 1984-06-22 1991-05-15 Sandoz Ag Pyrazolanaloge von mevalonolakton und abkoemmlinge davon, verfahren zu deren herstellung und deren verwendung.
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
US4808607A (en) * 1985-05-22 1989-02-28 Sandoz Pharm. Corp. Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte

Also Published As

Publication number Publication date
EP0433842A2 (en) 1991-06-26
IT8922768A1 (it) 1991-06-21
IT8922768A0 (it) 1989-12-21
JPH04210682A (ja) 1992-07-31
US5081136A (en) 1992-01-14
EP0433842A3 (en) 1992-01-08

Similar Documents

Publication Publication Date Title
IT1237793B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3770345D1 (de) Inhibitoren von hmg-coa-reduktase.
NO882218D0 (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
DE3681991D1 (de) Hmg-coa-reduktase-hemmungskoerper.
NO914092D0 (no) Fremgangsmaate for fremstilling av mercaptoacetylamidderivater
EP0859614A4 (en) INHIBITOR OF ROTAMASE ENCYMACTIVITY
NO931795L (no) Dobbeltvirkende inhibitorer
MC2313A1 (fr) Inhibiteurs d'enzymes
EP0567088A3 (en) Process for the preparation of an amylase inhibitor.
MX9203768A (es) Inhibidores novedosos de reductasa 3-hidroxi-metilglutaril-coenzima a.
IT1237792B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3881373D1 (de) Hmg-coa-reduktase-hemmer.
EP0994707A4 (en) INHIBITORS OF NAALADASE ENZYME ACTIVITY
NO882219L (no) Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer.
MX9100998A (es) Novedosos inhibidores de escualen sintetasa
DE68900988D1 (de) Hmg-coa-reduktase-inhibitoren.
FI893004A7 (fi) 5-oksygenoituja HMG-CoA-reduktaasi-inhibiittoreita
NO932850L (no) Fremgangsmaate for fremstilling av staal
ZA886468B (en) Novel hmg-coa reductase inhibitors
IT8419141A0 (it) Procedimento per la preparazione dell'estere metilico di alfa-l-aspartil-l-fenilalanina.
FI962235L (fi) Uudet bentseenisulfonyyli-imiinijohdannaiset IL-1:n toiminnan inhibiittoreina
FI945290L (fi) Menetelmä ribonukleotidireduktaasi-inhibiittoreiden valmistamista varten
ITMI921854A0 (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
DE3869282D1 (de) Inhibitoren von hmg-coa-reduktase.
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina

Legal Events

Date Code Title Description
0001 Granted